Welcome to our dedicated page for ENZOLYTICS news (Ticker: ENZC), a resource for investors and traders seeking the latest updates and insights on ENZOLYTICS stock.
ENZOLYTICS INC (ENZC) is a cutting-edge company focused on transitioning from drug development to sales, marketing, and distribution of medical devices, testing technology, and nutraceuticals. With recent investments in technologies like Room Temperature Single Photon Avalanche Diode (SPAD) and silicon photonics, the Company aims to revolutionize various industries including medical diagnostics, Lidar, AI computing, and space exploration.
Under the leadership of key executives like Harry Zhabilov, Barry Kostiner, and Steve Sharabura, ENZC is strategically collaborating with partners to drive innovation and bring transformative technologies to market. The recent investments and partnerships highlight the Company's commitment to growth, technological advancement, and improving patient well-being.
Enzolytics commemorates World AIDS Day, emphasizing the urgency for more effective HIV treatments. Currently, 1.2 million in the U.S. and 37.7 million globally are living with HIV, primarily relying on costly antiretrovirals. The company advances two promising therapies: ITV-1, a patented antiviral with significant clinical results, and monoclonal antibodies developed using Artificial Intelligence to target conserved HIV sites. Enzolytics is progressing towards regulatory approvals in Europe and North America, aiming to address both HIV and COVID-19 with its innovative technologies.
Enzolytics, Inc. (OTC PINK:ENZC) has announced the upcoming production and sale of Enzolytics IPF Immune, a liquid nutritional supplement aimed at enhancing immune function in the U.S. and North America. This product, derived from FDA-registered pepsin fragments, has shown effectiveness against various diseases and exhibits antiviral properties against HSV-1 and CoV-Sars-2. The company holds a 15-year license for U.S. marketing under its U.S. Patent No. 8,309,072. The North American dietary supplements market is projected to grow significantly, and Enzolytics aims to capitalize on this trend.
Enzolytics, Inc. (OTC PINK:ENZC) announced a protocol to produce monoclonal antibodies for veterinary use utilizing Hybridoma and Phage Display Technologies. The protocol leverages AI to analyze amino acid sequences of various viruses, identifying conserved target sites for antibody production. The company is producing antibodies in three phases, targeting viruses like HIV, Equine Infectious Anemia, and others. Enzolytics is exploring collaborations with veterinary companies to advance these therapies.
Enzolytics, Inc. (OTC PINK:ENZC) has finalized agreements with Danhson and Clinic Design to advance its anti-HIV therapeutic, ITV-1, toward production and clinical trials. Production at Danhson's facilities is expected in the coming months, followed immediately by clinical trials guided by Pharmalex. The company is also establishing the International Medical Partners (IMPL), of which it holds a 50% stake, to fund ITV-1's production and clinical trial costs. IMBL will exclusively distribute ITV-1 in EU member countries and select neighboring nations. A two-year audit is ongoing without issues.
Enzolytics, Inc. (OTC PINK:ENZC) has appointed Steve Sharabura as President of its subsidiary RobustoMed, Inc. to drive revenue and partnership growth in international markets, particularly in Brazil and Costa Rica. Mr. Sharabura brings over 30 years of experience in technology sales and international affairs, including leading major outreach efforts for a UN agency. His focus will be on establishing partnerships to expand RobustoMed's presence in medical development. The company aims for significant growth in this new business segment.
Enzolytics (OTC PINK:ENZC) has partnered with Lonza Bioscience to accelerate the development of anti-HIV and anti-SARS-CoV-2 monoclonal antibodies. This collaboration will utilize Lonza's advanced manufacturing technologies to streamline production, significantly reducing the development timeline for clinical trials. Enzolytics employs Artificial Intelligence to analyze virus sequences, identifying conserved sites for targeted treatments. The partnership aims to facilitate rapid clinical applications of fully human monoclonal antibodies, enhancing therapeutic options for infectious diseases.
Enzolytics (OTC PINK:ENZC) has signed a Letter of Intent with Creative Biolabs to collaborate on the production and commercialization of HTLV-1 monoclonal antibodies. Utilizing its proprietary AI technology, Enzolytics aims to develop targeted therapies for HTLV-1, a virus affecting over 20 million worldwide. Creative will handle testing, mass production, and marketing of these antibodies, sharing net profits with Enzolytics. This partnership enhances Enzolytics' capabilities in creating therapeutics for multiple infectious diseases.
Enzolytics, Inc. (OTC PINK:ENZC) has initiated plans to advance its ITV-1 anti-HIV therapy towards clinical trials and distribution in Europe. Significant positive results from previous clinical trials have boosted confidence in upcoming EMA trials. Key developments include forming International Medical Partners Ltd. for distribution, engaging Danhson Ltd. for production, and Clinical Design Ltd. for trial protocol preparation, with costs covered by European partners. The company aims to provide more effective and affordable HIV treatments compared to existing antiretrovirals.
Enzolytics, Inc. (OTC PINK:ENZC) has outlined a detailed protocol aimed at developing therapeutic cures for HIV and addressing future pandemics through a collaboration with Intel Corporation. Their strategy incorporates the use of Artificial Intelligence (A.I.) to analyze viral structures, identifying key target sites for monoclonal antibody production. The protocol has successfully screened over 87,336 HIV isolates and aims to create effective monoclonal antibody cocktails. Enzolytics is also pursuing partnerships in biotechnologies to further enhance its drug development initiatives.
Enzolytics, Inc. (OTC PINK:ENZC) announced the identification of conserved, immutable sites on the HTLV-1 virus for targeted monoclonal antibody production. No vaccines or antivirals exist for HTLV-1, which affects over 20 million people worldwide, with a significant percentage developing severe disease. Utilizing proprietary AI technology, the company aims to create a cocktail of fully human anti-HTLV-1 monoclonal antibodies to provide effective therapy. The research will occur at Texas A&M University, enhancing the company's platform for developing treatments for infectious diseases.
FAQ
What is the current stock price of ENZOLYTICS (ENZC)?
What is the market cap of ENZOLYTICS (ENZC)?
What is ENZOLYTICS INC (ENZC) focused on?
Who are some key executives leading ENZOLYTICS INC?
What recent investments has ENZOLYTICS INC made?
In which industries is ENZOLYTICS INC making an impact?
What is the Company's commitment?
